Cargando…

Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma

SIMPLE SUMMARY: The evaluation of tumor response to anti-cancer therapy is critical in oncology for the prompt determination of subsequent treatment and follow-up strategies. Historically, response criteria have been based on tumor size changes; however, since the development of locoregional and mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Faccia, Mariella, Garcovich, Matteo, Ainora, Maria Elena, Riccardi, Laura, Pompili, Maurizio, Gasbarrini, Antonio, Zocco, Maria Assunta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833342/
https://www.ncbi.nlm.nih.gov/pubmed/35158749
http://dx.doi.org/10.3390/cancers14030481
_version_ 1784648912286515200
author Faccia, Mariella
Garcovich, Matteo
Ainora, Maria Elena
Riccardi, Laura
Pompili, Maurizio
Gasbarrini, Antonio
Zocco, Maria Assunta
author_facet Faccia, Mariella
Garcovich, Matteo
Ainora, Maria Elena
Riccardi, Laura
Pompili, Maurizio
Gasbarrini, Antonio
Zocco, Maria Assunta
author_sort Faccia, Mariella
collection PubMed
description SIMPLE SUMMARY: The evaluation of tumor response to anti-cancer therapy is critical in oncology for the prompt determination of subsequent treatment and follow-up strategies. Historically, response criteria have been based on tumor size changes; however, since the development of locoregional and molecular-targeted therapies in HCC (which act by disrupting tumor vascularization rather than tumor cells), changes in tumor vascularity and enhancement patterns have been considered to be more reliable. Contrast-enhanced ultrasound (CEUS) and dynamic CEUS, which allow microvessel perfusion studies, are emerging as promising tools for early tumor response evaluation. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure at different stages of the disease. ABSTRACT: The capacity of contrast-enhanced ultrasound (CEUS) to detect microvessel perfusion has received much attention in cancer imaging since it can be used to evaluate the enhancement patterns of the lesions during all vascular phases in real time, with higher temporal resolution as compared other imaging modalities. A rich body of literature has demonstrated the potential usefulness of CEUS in the assessment of HCC in response to both locoregional and systemic therapies. It is useful to evaluate the efficacy of ablation immediately after treatment to provide guidance for the retreatment of residual unablated tumors. In patients treated with transarterial chemoembolization (TACE), CEUS showed a high degree of concordance with computed tomography and magnetic resonance for the differentiation of responders from non-responders. Dynamic CEUS (D-CEUS) has emerged as a promising tool for the depicting changes in tumor perfusion during anti-angiogenetic treatment that can be associated with tumor response and clinical outcome. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure in different stages of the disease.
format Online
Article
Text
id pubmed-8833342
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88333422022-02-12 Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma Faccia, Mariella Garcovich, Matteo Ainora, Maria Elena Riccardi, Laura Pompili, Maurizio Gasbarrini, Antonio Zocco, Maria Assunta Cancers (Basel) Review SIMPLE SUMMARY: The evaluation of tumor response to anti-cancer therapy is critical in oncology for the prompt determination of subsequent treatment and follow-up strategies. Historically, response criteria have been based on tumor size changes; however, since the development of locoregional and molecular-targeted therapies in HCC (which act by disrupting tumor vascularization rather than tumor cells), changes in tumor vascularity and enhancement patterns have been considered to be more reliable. Contrast-enhanced ultrasound (CEUS) and dynamic CEUS, which allow microvessel perfusion studies, are emerging as promising tools for early tumor response evaluation. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure at different stages of the disease. ABSTRACT: The capacity of contrast-enhanced ultrasound (CEUS) to detect microvessel perfusion has received much attention in cancer imaging since it can be used to evaluate the enhancement patterns of the lesions during all vascular phases in real time, with higher temporal resolution as compared other imaging modalities. A rich body of literature has demonstrated the potential usefulness of CEUS in the assessment of HCC in response to both locoregional and systemic therapies. It is useful to evaluate the efficacy of ablation immediately after treatment to provide guidance for the retreatment of residual unablated tumors. In patients treated with transarterial chemoembolization (TACE), CEUS showed a high degree of concordance with computed tomography and magnetic resonance for the differentiation of responders from non-responders. Dynamic CEUS (D-CEUS) has emerged as a promising tool for the depicting changes in tumor perfusion during anti-angiogenetic treatment that can be associated with tumor response and clinical outcome. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure in different stages of the disease. MDPI 2022-01-18 /pmc/articles/PMC8833342/ /pubmed/35158749 http://dx.doi.org/10.3390/cancers14030481 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Faccia, Mariella
Garcovich, Matteo
Ainora, Maria Elena
Riccardi, Laura
Pompili, Maurizio
Gasbarrini, Antonio
Zocco, Maria Assunta
Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
title Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
title_full Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
title_fullStr Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
title_full_unstemmed Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
title_short Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
title_sort contrast-enhanced ultrasound for monitoring treatment response in different stages of hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833342/
https://www.ncbi.nlm.nih.gov/pubmed/35158749
http://dx.doi.org/10.3390/cancers14030481
work_keys_str_mv AT facciamariella contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma
AT garcovichmatteo contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma
AT ainoramariaelena contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma
AT riccardilaura contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma
AT pompilimaurizio contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma
AT gasbarriniantonio contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma
AT zoccomariaassunta contrastenhancedultrasoundformonitoringtreatmentresponseindifferentstagesofhepatocellularcarcinoma